Free Trial
NASDAQ:CDIO

Cardio Diagnostics Q3 2025 Earnings Report

Cardio Diagnostics logo
$1.98 +0.02 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$1.98 0.00 (0.00%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$0.98
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.15 million
Beat/Miss
Missed by -$147.00 thousand
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Cardio Diagnostics Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile